Novel use of oral chloramphenicol for treatment-resistant Mycoplasma genitalium.
Sex Transm Infect
; 99(3): 208-210, 2023 05.
Article
em En
| MEDLINE
| ID: mdl-36717253
ABSTRACT
We describe the novel use of oral chloramphenicol for treatment-resistant Mycoplasma genitalium (M. genitalium) infection in a 20-year-old heterosexual cisgender male presenting with recurrent symptomatic non-gonococcal urethritis. M. genitalium urethritis is an increasingly common clinical conundrum in sexual health clinics and in cases of second-line treatment failure (such as moxifloxacin), UK and international guidelines struggle to make recommendations for third-line treatments. As shown in our case, the evidence base for third-line treatments is lacking, with poor success rates, and may be poorly tolerated. Here we demonstrate the novel use of a well-tolerated oral antimicrobial, chloramphenicol, resulting in rapid microbiological and clinical cure in treatment-resistant M. genitalium urethritis.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Uretrite
/
Mycoplasma genitalium
/
Anti-Infecciosos
/
Infecções por Mycoplasma
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article